Upfront Briefing
Sanofi’s venglustat picked up FDA Breakthrough Therapy designation in type 3 Gaucher disease — the kind of label that can compress timelines and nudge pipeline math.
On the tape of capital and regulation: CytomX priced a $250M public offering, while Aldeyra took a third FDA rejection on reproxalap — a combination of balance-sheet extension and outright franchise pressure.
Tape Action
| Instrument |
Last close |
1D % |
YTD % |
| S&P 500 |
6,716.1 |
+0.3% |
(1.9%) |
| Nasdaq 100 |
24,780.4 |
+0.1% |
(1.9%) |
| Russell 2000 |
2,520.0 |
+0.7% |
+1.5% |
| Healthcare (XLV) |
149.6 |
(0.9%) |
(3.3%) |
| Biotech (XBI) |
124.2 |
+0.2% |
+1.9% |
| Nasdaq Biotech (NBI) |
5,777.4 |
0.0% |
+1.2% |
| Clinical Trials (BBC) |
41.1 |
(0.9%) |
+6.6% |
|
-
Broad equities ground higher into the Fed despite persistent oil and inflation noise: the S&P 500 closed +0.3%, with travel and airline names helping offset macro nerves.
-
Healthcare stayed on the back foot: XLV fell (0.9%), while biotech held in relatively better, with XBI up +0.2% and NBI flat — a sign investors were willing to own idiosyncratic biotech setups even as defensive healthcare lagged.
-
Small caps also outperformed: Russell 2000 rose +0.7%, consistent with a modest risk-on bid rather than a pure flight to quality.
- Market data: U.S. close 2026-03-17.
The Big 3
|
1
|
CytomX Therapeutics prices $250M public offering
|
-
CytomX Therapeutics has priced a $250 million public offering, including common stock and pre-funded warrants.
-
Why it matters:
For CytomX, this is less about “raising cash” than buying strategic time. A $250M offering materially de-risks near-term financing overhang, funds Varseta-M and the rest of the pipeline, and gives management a cleaner window to convert recent CRC data into a development path — but at the cost of meaningful dilution that likely resets the stock’s near-term ceiling.
-
Source:
PR
|
|
2
|
Sanofi's venglustat gets FDA Breakthrough Therapy designation
|
-
Sanofi's venglustat has received FDA Breakthrough Therapy designation for type 3 Gaucher disease.
-
Why it matters:
Breakthrough Therapy designation matters here because it sharpens the regulatory path for an asset with phase 3 data in a rare disease with no approved therapy for neurological symptoms. For investors, the read-through is improved visibility on timeline, higher program credibility, and a better chance that the market starts underwriting venglustat as a real contributor rather than an orphan optionality stub.
-
Source:
PR
|
|
3
|
FDA rejects Aldeyra’s dry eye drug reproxalap for a third time
|
-
The FDA declined to approve Aldeyra’s dry eye disease candidate reproxalap, citing insufficient efficacy; Aldeyra said it plans a Type A meeting with the agency.
-
Why it matters:
A third CRL moves this from “timing setback” to franchise impairment. For investors, the issue is not just delay but whether reproxalap is still a credible approval asset at all — which can force a full reset of probability-of-success, partnering assumptions and terminal value for the program.
-
Source:
Reuters
|
Everything Else that broke
- Innorna gets FDA IND clearance for IN026, an mRNA therapy for refractory gout. — PR
- BioVersys reports 2025 financial results and pipeline progress. — PR
- Beyond Cancer reports interim Phase 1 UNO trial data. — PR
- CytomX’s Varseta-M update continues to support the post-data financing window. — BioPharma Dive
Deal Flow
|
BioBucks 2026 Deal Trackers • Updated weekly
⬇️
|
M&A / BD&L
- Alebund licenses AP306 ex-Greater China to newly launched R1 Therapeutics; terms include up to low triple-digit millions in milestones plus low double-digit royalties. — PR
VC / Private Financings
- R1 Therapeutics launches with an oversubscribed $77.5M Series A. Led by Abingworth, DaVita Venture Group and F-Prime; joined by Curie.Bio, SymBiosis and U.S. Renal Care. — Fierce
IPOs / Follow-Ons
- CytomX Therapeutics prices $250M public offering; Jefferies, Piper Sandler, Cantor and Barclays lead. — PR
- SAB BIO prices $85M public offering of common stock and pre-funded warrants. — PR
Academic Corner
- FDA backpedals to review Moderna mRNA flu vaccine. — Nature Biotech
- New rules spur cell and gene therapy trials in China. — Nature Biotech
- BBB Hunter agent nears FDA decision. — Nature Biotech
- Mass azithromycin distribution and antibiotic resistance in the gut and nasopharynx: a cluster-randomized trial. — Nature Medicine
|
